Disease Overview：IgA nephropathy（IgAN）
IgA nephropathy (IgAN), also known as Berger’s disease, is a chronic glomerulonephritis characterized by mesangial deposition of immunoglobulin A (IgA) immune complexes, leading to progressive inflammation and scarring of the glomeruli. It is the most common primary glomerular disease worldwide and a leading cause of end-stage kidney disease (ESKD). Clinical presentation varies widely—from asymptomatic microscopic hematuria and mild proteinuria to nephrotic-range proteinuria, hypertension, and declining estimated glomerular filtration rate (eGFR). Diagnosis relies on renal biopsy with immunofluorescence confirmation of dominant or codominant IgA deposits in the mesangium. Prognosis is heterogeneous; risk stratification incorporates factors such as proteinuria level (>1 g/day), eGFR at diagnosis, hypertension, and histopathologic features (e.g., Oxford MEST-C score). While supportive care—including ACE inhibitors/ARBs, SGLT2 inhibitors, and blood pressure control—forms the foundation, emerging therapies like targeted-release budesonide (Nefecon) and complement inhibitors are now integrated into personalized treatment pathways in advanced centers.
China offers distinct advantages for international patients seeking IgA nephropathy management. Leading nephrology centers—such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—combine deep expertise in glomerular disease with access to next-generation diagnostics (e.g., digital pathology, urinary proteomics) and early-access clinical trials. Outcomes data demonstrate comparable or superior 5- and 10-year renal survival rates versus Western benchmarks, particularly among patients receiving protocol-driven, multidisciplinary care. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based standards—generic biologics, subsidized immunosuppressants, and streamlined hospital workflows contribute significantly to this value proposition. As a dedicated medical tourism agency, we facilitate seamless access: verifying physician credentials, coordinating biopsy interpretation and treatment planning across top-tier hospitals, providing transparent, all-inclusive pricing (covering consultations, diagnostics, medications, and follow-up), and offering end-to-end support—from visa assistance and accommodation to bilingual nursing liaison and post-discharge telehealth coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown for IgA Nephropathy (Nephrology Department)
Non-Surgical / Conservative / Medication-Based Management
*Target criteria:* eGFR ≥30 mL/min/1.73m², proteinuria ≥0.5 g/day, stable BP, no active crescentic glomerulonephritis
- •First-line therapy (RAS blockade)
- Renal function + urine ACR monitoring (q3mo): $16–$22 per visit - Serum potassium & creatinine (baseline + q3mo): $12–$18 per panel
- •Second-line immunosuppression (for persistent proteinuria ≥1 g/day despite RASi)
- *Mycophenolate mofetil (MMF)*: 3-month supply (1g bid): $112–$168 - *Monitoring labs (monthly for 3 mo, then q2mo)*: CBC, LFTs, serum creatinine, albumin: $24–$32 per panel
- •SGLT2 inhibitors (eGFR ≥25 mL/min/1.73m²)
- Ketone testing strips (3-month supply): $18–$24
Surgical / Procedural / Interventional Options
*Eligibility:* Rapidly progressive IgAN with >50% crescents on biopsy *and* eGFR <50 mL/min/1.73m² *or* nephrotic-range proteinuria unresponsive to 6 months of optimized medical therapy
- •Plasma exchange (PLEX) – 7 sessions over 2 weeks
- Total (7 sessions): $1,960–$2,940 - Preoperative workup (ANA, ANCA, anti-GBM, coagulation panel, albumin, IgA levels): $142–$198
- •Renal biopsy (diagnostic or repeat)
- Pre-biopsy: PT/INR, platelet count, renal ultrasound: $84–$112
Special / Complex Condition Management
- •End-stage IgAN (eGFR <15 mL/min/1.73m²)
- Peritoneal dialysis setup + 1-month CAPD supplies: $1,680–$2,240
- •IgAN with severe hypertension (BP ≥180/110 mmHg) + left ventricular hypertrophy
- Cardiac echo (nephrology-ordered): $112–$168
Quick Selection Guide
- •Young adult (<40), low-budget, mild proteinuria (0.5–1 g/day), no HTN: Start with RAS blockade + SGLT2i — annual cost: $320–$480
- •Middle-aged (45–65), moderate severity (proteinuria 1.5–3 g/day), DM or HTN comorbidity: RASi + MMF + SGLT2i — annual cost: $2,100–$3,200
- •Elderly (>70), rapid decline (eGFR drop >5 mL/min/yr), crescentic IgAN: PLEX + steroids — initial 3-month cost: $2,800–$4,100
- •ESRD patient with limited mobility: Peritoneal dialysis — first-year total: $12,600–$16,800 (includes training, catheter placement, monthly supplies)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended IgA nephropathy Medical Vacation Packages
Curated transparent all-inclusive packages combining IgA nephropathy treatment with China top medical destinations:
